A young lady with seronegative systemic lupus erythematosus
Journal Title: International Journal of Clinical Rheumatology - Year 2017, Vol 12, Issue 2
Abstract
Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease. It is a multisystem disease which can involve any organ in the body. Most of the SLE cases are seropositive which depend on positive test for antinuclear antibody (ANA), Lupus erythematous (LE) cells, and antibody to DNA but seronegative SLE cases also rarely can present with complications.
Authors and Affiliations
De Zoysa HDJ, Peranantharajah T, Aravinthan v, Nisahan B
Keywords
Related Articles
- EP ID EP603284
- DOI -
- Views 67
- Downloads 0
Small fiber neuropathy as a part of fibromyalgia or a separate diagnosis?
Fibromyalgia (FM) is a chronic disease characterized mainly by widespread pain, fatigue and cognitive disorders. Small Fiber Neuropathy (SFN) is a generalized sensory nerve disorder with structural and functional nerve a...
Serum vitamin D in Egyptian patients with systemic lupus erythematous and its association with lupus nephritis
Aim: To assess VD levels in serum of patients with LN in comparison with patients with extra-renal lupus and healthy controls, and to assess the relation between VD levels and the various clinical and laboratory disease...
The effect of hydroxychloroquine on endothelial dysfunction in patients with rheumatoid arthritis: A doubleblind randomized clinical trial
Aim: The aim of this study was to evaluate the effect of hydroxychloroquine on endothelial dysfunction in rheumatoid arthritis patients by measuring soluble vascular cell adhesion molecule-1 (sVCAM-1) and soluble E-Selec...
Targeted gene therapy in the management of osteoarthritis: back to the future with great expectations
Osteoarthritis (OA) is a degenerative joint disease of the articular cartilage with subchondral bone remodeling and secondary inflammation [1]. OA is the most common joint disease worldwide, a chief cause of chronic disa...
Adalimumab induced chronic interstitial nephritis: a controlled blinded trial in mice
Background: Adalimumab is a known drug modifying agent for rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA) treatment. However little is known about the risk of nephrotoxicity. To determine whether the i...